AUG 11, 2016 11:00 AM PDT
RNA-ISH for Long non-coding RNAs - new game changers in pathology
SPONSORED BY: Advanced Cell Diagnostics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE
11 25 2497

Speakers:
  • Assistant Professor of Pathology Member-Michigan Center for Translational Pathology MLabs Genitourinary Service Line Director Co-Director, University of Michigan Rapid Autopsy Discovery Progr
    Biography
      Dr. Rohit Mehra is an Assistant Professor in Department of Pathology at the University of Michigan and a faculty member at Michigan Center for Translational Pathology (MCTP). In addition to routine clinical and diagnostic responsibilities, Dr. Mehra serves as MLabs' Genitourinary (GU) Service Line Director and is also Co-Director of University of Michigan Rapid Autopsy Discovery Program. Dr. Mehra completed his residency in anatomic pathology at the University of Michigan in 2011 after first serving for five years as a research investigator in the laboratory of Dr. Arul Chinnaiyan, Director of MCTP. Dr. Mehra completed fellowship training in GU pathology at Memorial Sloan Kettering Cancer Center under the Direction of Dr. Victor Reuter.
      Working with colleagues at MCTP, Dr. Mehra played an important role in discovery of recurrent fusion of TMPRSS2 and ETS transcription factor genes, now recognized as an important driver mutation in prostate carcinomas. He has continued to focus on the mutational landscape of malignant GU neoplasms as well as biomarkers important for diagnosis and management of affected patients. Over the last decade he has served as the author of more than 100 publications in the peer-reviewed literature, several book chapters, and abstracts. Dr. Mehra has been invited on numerous occasions to deliver extramural, national and international presentations. To facilitate clinical translation of emerging molecular advances in GU malignancies, Dr. Mehra has helped launch novel, clinically significant molecular oncology results into assays for diagnostic, prognostic, and/or therapeutic use.

    Abstract:
    DATE: August 11, 2016
    TIME: 11:00AM PST, 2:00PM ET, 7:00PM GMT



    The central dogma that forms the backbone of molecular biology is that DNA codes for RNA (transcription) which then codes for proteins (translation). However, studies over the last few years demonstrated that just 1.5% of the 3 billion base pairs of DNA constituting the human genome generate the ~20,000 protein coding genes, whereas at least 90% of genome is transcribed into non-coding RNA (ncRNA) that does not result in a protein product.  The rapid characterization of numerous ncRNAs has dramatically altered our understanding of biology.  The discovery of long ncRNAs (lncRNAs, longer than 200 nucleotides) as mediators of various cellular processes as well as various human pathophysiologic processes including cancer has established their role as critical biological entities.  Several lncRNAs have been linked to oncogenesis; for example, HOTAIR in breast and colon cancer, and SChLAP1, PCAT-1 and ANRIL in prostate cancer. SChLAP1 in situ hybridization (RNA-ISH) has been recently demonstrated by our group to be a novel tissue-based biomarker assay for outcome prognostication after radical prostatectomy that carries great clinical promise to help direct risk stratification for patients with prostate cancer. Because RNA-ISH assay is evaluated using a light microscope, it not only allows detection of lncRNA of interest, it provides insight into the localization of the lncRNA as well. Overall, a myriad of lncRNAs are associated with carcinogenesis and RNA-ISH provides a practical tool for clinical application of lncRNA markers of interest in situ.

    Learning Objectives
    1. Understand the clinical potential and utility of lncRNAs
    2. Become familiar with RNA-ISH as a clinical translational too

    Show Resources
    Loading Comments...